As the new year approaches, the profit-making effect of the pharmaceutical and medical sector continues to spread, especially the Chinese patent medicine and API enterprises with partial superposition of the concept of price rise and small market value.
The main board Kunming Longjin Pharmaceutical Co.Ltd(002750) (002750. SZ) is upgraded to 7-connected boards, and Jinghua Pharmaceutical Group Co.Ltd(002349) (002349. SZ) is 5-connected boards; In the gem, Gansu Longshenrongfa Pharmaceutical Industry Co.Ltd(300534) (300534. SZ) intermittently harvest 5 trading boards; The three pharmaceutical stocks (830946. BJ), Datang Pharmaceutical (836433. BJ) and Lude medical (832278. BJ) of the Beijing stock exchange also had a “30cm” limit.
It is worth noting that senxuan pharmaceutical closed two trading boards on December 29 and 30, and the yield on the 5th reached 148.42%. It is said in the market that senxuan medicine is one of the components of Pfizer covid-19 specific drugs and the main manufacturer of ritonavir API. However, the company issued an announcement on the 30th to remind investors that it has not signed a purchase and sales contract related to ritonavir pharmaceutical intermediates with Pfizer. Please invest rationally and pay attention to risks.
no relevant purchase and sales contract has been signed with Pfizer
Senxuan pharmaceutical is the API subsidiary of Jinghua Pharmaceutical Group Co.Ltd(002349) A-share listed company, Jinghua Pharmaceutical Group Co.Ltd(002349) holds 72.31% equity of the company. To some extent, the rise of senxuan medicine is also related to the hot trend of the parent company in a shares.
However, the direct reason for the emergence of senxuan medicine is that recently, FDA announced that it urgently authorized Pfizer to independently develop oral covid-19 drug paxlovid. Its main components include ritonavir, and senxuan medicine’s products happen to include ritonavir intermediate.
Similarly, the previous Xinxiang Tuoxin Pharmaceutical Co.Ltd(301089) (301089. SZ) was falsely rumoured as the uridine supplier of molnupiravir, a drug of MSD covid-19. The above news has also become the lead of the current round of stock price changes of senxuan medicine.
The Board Secretary of Jinghua Pharmaceutical Group Co.Ltd(002349) once said when answering investors’ questions on February 6, 2020: “the annual production capacity of the main intermediate of senxuan pharmaceutical ritonavir, a subsidiary of the company, is about 30 tons. According to the preliminary investigation and statistics of senxuan pharmaceutical, at present, the market share of this kind of intermediate is about 70%, ranking first in the same industry in China.”
In November 19th, institutional investors investigated the impact of Pfizer COVID-19 oral medicine on the company in the research activities of Sen Xuan medicine. At that time, Sen Xuan responded that the company’s current products are mainly used in the synthesis of ritonavir, an anti AIDS drug, and the dosage and efficacy of ritonavir in the specific formulation of Pfizer COVID-19. There are uncertainties in the certification of FDA, the selection of Pfizer API suppliers after mass production and the selection of intermediate suppliers by ritonavir API manufacturers. The company will actively participate in and pay close attention to the market and orders.
However, on Sunday, Sen Xuan pharmaceuticals clarified the connection with Pfizer COVID-19 on the 30 day: at present, the company has not signed a contract for the purchase and sale of ritonavir medicine intermediates with Pfizer Inc, and has not supplied the ritonavir series intermediates. The ritonavir series intermediates sold by the company are mainly used in the synthesis of the anti HIV drug ritonavir.
In fact, in 2021, ritonavir pharmaceutical intermediate of senxuan medicine not only did not grow, but also declined. In its reply, it disclosed that the sales volume is expected to be 11 tons in 2021, and the sales revenue is expected to be 16.84 million yuan, with a year-on-year decrease of about 33% and 32% respectively.
has attracted regulatory attention
Senxuan pharmaceutical is not the only one that investors associate with Pfizer as a supplier of API. It is understood that covid-19 drug paxlovid is a compound preparation of 3CL protease inhibitor pf-07321332 and low-dose ritonavir, and carbonic anhydride is one of the intermediates for the synthesis of pf-07321332. This makes Aba Chemicals Corporation(300261) (300261. SZ) change.
For seven consecutive trading days from December 20, 2021 to December 28, 2021, the deviation of Aba Chemicals Corporation(300261) closing price increase has reached 105.66%. Subsequently, Aba Chemicals Corporation(300261) announced that due to the recent serious abnormal fluctuation of the company’s share price, the trading of the company’s shares has been suspended since the opening of the market on December 29, 2021 and resumed after the disclosure of the verification announcement.
In addition, Aba Chemicals Corporation(300261) also received a letter of concern from the Shenzhen Stock Exchange on December 23, which was asked to explain whether there was an indirect provision of carlon anhydride products to Pfizer. Aba Chemicals Corporation(300261) also replied to the Shenzhen Stock Exchange on December 28 that Aba Chemicals Corporation(300261) did not sign any cooperation agreement with Pfizer, had no cooperative relationship with Pfizer, and did not supply carlon anhydride and its derivatives to Pfizer. The customers of the company’s carbonic anhydride and its derivatives are mainly Chinese customers and Indian customers, and it is uncertain whether it is indirectly supplied to Pfizer.
Shortly before the stock price soared, Wang Xinya, one of the actual controllers of Aba Chemicals Corporation(300261) , reduced 19 million shares of the company through block trading on November 30, with a reduction ratio of 1.97% and an average reduction price of 7.24 yuan. The Shenzhen Stock Exchange also asked Aba Chemicals Corporation(300261) to verify and explain to the shareholders the reasons for the reduction and the use of funds, whether there is any suspected insider trading, and whether there is any use of information disclosure to hype the stock price.
The reporter also found that in addition to the stocks that have changed, some enthusiastic investors have also asked pharmaceutical companies that may have related businesses on the investor exchange platform, trying to tap potential suppliers of Pfizer covid-19 drugs, but they have been denied by the company.
(Daily Economic News)
